Facebooktwitterredditlinkedinmail
image_printPrint Page

Victoza pen

Updated Label of Liraglutide for Obesity in Adolescents

The use of a GLP-1 receptor agonist for adolescents aged 12-17 years and adults who are struggling with uncontrollable hunger and/obesity has been FDA approved. It is an updated label for liraglutide 3 mg. The prescription is available in an injector pen for daily use. The 3 mg daily dose was approved in 2014 for chronic weight management in adults who met BMI criteria and had at least one weight-related comorbidity. With the updated label, this GLP-1 is the first FDA-approved therapy for adolescents with obesity in more than a decade.

Obesity in both children and adults is a growing epidemic. As Aaron S. Kelly, PhD, professor in the department of pediatrics and a co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota Medical School in Minneapolis said, 90% of adolescents with obesity become obese adults with an increased risk for developing weight-related complications.

The most common adverse reactions were gastrointestinal events, including nausea, vomiting, and diarrhea.

If you would like assistance with healthy weight loss give our office a call. We have a new wellness retainer that allows you to work with our dietitian, Dana, and clinical exercise physiologist, Kathryn. To set up an appointment give us a call at (USA) 877-735-3648

Outside the US: 001-610-642-6055.

For more information visit: https://www.healio.com/news/endocrinology/20201207/fda-approves-liraglutide-for-treating-obesity-in-adolescents

image_printPrint Page